Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Francesca Bonello"'
Autor:
Roberto Mina, Maria Teresa Petrucci, Francesca Bonello, Velia Bongarzoni, Riccardo Saccardi, Giuseppe Bertuglia, Andrea Mengarelli, Andrea Spadaro, Chiara Lisi, Paola Curci, Roberto Massimo Lemoli, Stelvio Ballanti, Rita Floris, Luca Cupelli, Patrizia Tosi, Attilio Olivieri, Delia Rota-Scalabrini, Clotilde Cangialosi, Chiara Nozzoli, Barbara Anaclerico, Francesca Fazio, Benedetto Bruno, Katia Mancuso, Paolo Corradini, Giuseppe Milone, Mario Boccadoro
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
High-dose melphalan plus autologous stem cell transplantation (ASCT) is a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), and adequate hematopoietic stem cell (HSC) collection is crucial to ensure hemat
Externí odkaz:
https://doaj.org/article/9166e5bc73e84f42bc5fc785d6d557e5
Autor:
Roberto Mina, Antonietta Pia Falcone, Sara Bringhen, Anna Marina Liberati, Norbert Pescosta, Maria Teresa Petrucci, Giovannino Ciccone, Andrea Capra, Francesca Patriarca, Delia Rota-Scalabrini, Francesca Bonello, Caterina Musolino, Michele Cea, Renato Zambello, Paola Tacchetti, Angelo Belotti, Claudia Cellini, Laura Paris, Mariella Grasso, Sara Aquino, Lorenzo De Paoli, Giovanni De Sabbata, Stelvio Ballanti, Massimo Offidani, Mario Boccadoro, Federico Monaco, Paolo Corradini, Alessandra Larocca
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021)
Externí odkaz:
https://doaj.org/article/85d07ceb4ffb4350a7da29ebc2f8331e
Autor:
Mattia D’Agostino, Alessandra Larocca, Massimo Offidani, Anna Marina Liberati, Gianluca Gaidano, Maria Teresa Petrucci, Daniele Derudas, Andrea Capra, Renato Zambello, Nicola Cascavilla, Paolo de Fabritiis, Vanessa Innao, Francesca Bonello, Francesca Patriarca, Giulia Benevolo, Nicola Giuliani, Gabriele Aitoro, Tommasina Guglielmelli, Francesco Di Raimondo, Paolo Corradini, Pellegrino Musto, Roman Hájek, Pieter Sonneveld, Mario Boccadoro, Sara Bringhen
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 4, Pp 1-5 (2021)
Externí odkaz:
https://doaj.org/article/2bfcf6a98cdd434897d6e066fb202482
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Multiple Myeloma (MM) is a hematologic malignancy characterized by a wide clinical and biological heterogeneity leading to different patient outcomes. Various prognostic tools to stratify newly diagnosed (ND)MM patients into different risk groups hav
Externí odkaz:
https://doaj.org/article/642eeb05eab541a9834730bae914cdee
Autor:
Francesca Bonello, Serena Rocchi, Gregorio Barilà, Michela Sandrone, Marco Talarico, Elena Zamagni, Matilde Scaldaferri, Susanna Vedovato, Cecilia Bertiond, Laura Pavan, Sara Bringhen, Francesco Cattel, Renato Zambello, Michele Cavo, Roberto Mina
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infu
Externí odkaz:
https://doaj.org/article/cebba398bc784e5b9511be823fd1fe9a
Autor:
Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, Anna Marina Liberati, Concetta Conticello, Stelvio Ballanti, Pellegrino Musto, Attilio Olivieri, Giulia Benevolo, Andrea Capra, Milena Gilestro, Piero Galieni, Michele Cavo, Agostina Siniscalchi, Antonio Palumbo, Vittorio Montefusco, Gianluca Gaidano, Paola Omedé, Mario Boccadoro, Sara Bringhen
Publikováno v:
Haematologica, Vol 106, Iss 4 (2020)
Despite remarkable advances in the treatment of multiple myeloma in the last decades, the prognosis of patients harboring high-risk cytogenetic abnormalities remains dismal as compared to that of standard-risk patients. Proteasome inhibitors demonstr
Externí odkaz:
https://doaj.org/article/cbd6ddd3ccbc4a94b1e8c8d5e8403a39
Publikováno v:
Clinical Hematology International, Vol 1, Iss 4 (2019)
The introduction of novel agents, characterized by favorable toxicity profiles and higher manageability compared to conventional drugs employed in the past, has considerably changed the treatment paradigm for multiple myeloma. Continuous therapy curr
Externí odkaz:
https://doaj.org/article/81b7569b28274446b2b6a3fbf198074d
Autor:
Francesca Bonello, Mariella Grasso, Mattia D’Agostino, Ivana Celeghini, Alessia Castellino, Mario Boccadoro, Sara Bringhen
Publikováno v:
Pharmaceuticals, Vol 14, Iss 1, p 20 (2020)
Elderly transplant-ineligible (NTE) patients represent the majority of patients affected by multiple myeloma (MM). Elderly patients are a highly heterogeneous population, with large variability in health and functional status. Thus, choosing their op
Externí odkaz:
https://doaj.org/article/6b99c98578204e119575b6d72be0576e
Publikováno v:
Cancers, Vol 12, Iss 11, p 3106 (2020)
Multiple myeloma (MM) mostly affects elderly patients, which represent a highly heterogeneous population. Indeed, comorbidities, frailty status and functional reserve may vary considerably among patients with similar chronological age. For this reaso
Externí odkaz:
https://doaj.org/article/3138fc7315384cb8bf8c8a6db187bd21
Autor:
Francesca Bonello, Stefano Pulini, Stelvio Ballanti, Massimo Gentile, Stefano Spada, Ombretta Annibali, Paola Omedé, Sonia Ronconi, Clotilde Cangialosi, Luigi Podda, Angelo Palmas, Alessandra Malfitano, Giulia Rivoli, Angelo Belotti, Fabrizio Ciambelli, Iolanda Donatella Vincelli, Anna Maria Cafro, Vanessa Innao, Antonio Palumbo, Pieter Sonneveld, Andrew Spencer, Roman Hájek, Mario Boccadoro, Francesca Gay
Publikováno v:
Cancers, Vol 11, Iss 11, p 1735 (2019)
We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly diagnosed transplant-eligible and -ineligible myeloma patients. Primary endpoints were prog
Externí odkaz:
https://doaj.org/article/ed93797a019a4e979e53548874942c76